Morgan Stanley Sees Ways for Medtronic to Create Value

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $73.00 price target on

. In the report, Morgan Stanley “In the wake of new tax rules, investors have questioned whether a different deal structure could preserve accretion. Our analysis shows ways for MDT to create value by either decreasing stock consideration or – counterintuitively – offering even more equity to sidestep inversion limits entirely.” Medtronic closed on Wednesday at $65.98.